Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 6,350 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Intestinal Disorders Clear all
Completed Phase 3 Interventional

Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer

NCT00003057
View directory record Official record
Conditions
Colorectal Cancer, Diarrhea
Interventions
loperamide hydrochloride, octreotide acetate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
33
States / cities
La Jolla, California • San Francisco, California • Wilmington, Delaware + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2023 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 1Phase 2 Interventional

Anti-Interleukin-5 (IL-5) Study for Hypereosinophilic Syndrome

NCT00266565
View directory record Official record
Conditions
Hypereosinophilic Syndromes, Eosinophilic Gastroenteritis, Churg-Strauss Syndrome, Eosinophilic Esophagitis
Interventions
Mepolizumab
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 29, 2020 · Synced Oct 20, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional Results available

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

NCT01507545
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colorectal Cancer
Interventions
MORAb-004, Placebo, Best supportive care
Drug · Other
Lead sponsor
Morphotek
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
67
States / cities
Alhambra, California • Bakersfield, California • Burbank, California + 54 more
Source: ClinicalTrials.gov public record
Updated May 6, 2022 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer

NCT00326495
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Cetuximab, BAY 43-9006
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 24, 2017 · Synced Oct 20, 2026, 7:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Investigational Study of Oral Fish Oil in Treating Parenteral Nutrition Associated Liver Disease

NCT01191177
View directory record Official record
Conditions
Liver Disease, Short Bowel Syndrome
Interventions
Lovaza (omega-3-acid ethyl ester), Corn oil
Drug · Dietary Supplement
Lead sponsor
Boston Children's Hospital
Other
Eligibility
30 Days to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2017 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 4 Interventional

Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease

NCT00280956
View directory record Official record
Conditions
Crohn's Disease
Interventions
natalizumab
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Oct 20, 2026, 7:15 AM EDT
Completed No phase listed Observational

Observational Study of Kibow Biotics in Chronic Kidney Failure Patients

NCT01450657
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Kibow Biotics/Renadyl
Dietary Supplement
Lead sponsor
Kibow Pharma
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 20, 2026, 7:15 AM EDT
Terminated Phase 2 Interventional

Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer

NCT00459901
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Erlotinib and capecitabine
Drug
Lead sponsor
Peter Kozuch
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2015 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)

NCT00600119
View directory record Official record
Conditions
Opioid Induced Constipation (OIC)
Interventions
placebo, NKTR-118
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Pinson, Alabama • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2015 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Choice on Colorectal Cancer Screening

NCT05275530
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Neoplasms, Health Screening
Interventions
Active FIT Choice, Active Colonoscopy Choice, Active Dual Choice
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
45 Years to 49 Years
Enrollment
20,509 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Los Angeles, California • Westwood, Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Oct 20, 2026, 7:15 AM EDT
Completed No phase listed Observational

Anal Cancer Screening Study

NCT00914537
View directory record Official record
Conditions
Anal Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 110 Years · Male only
Enrollment
363 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 6, 2020 · Synced Oct 20, 2026, 7:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer

NCT06307548
View directory record Official record
Conditions
Locally Advanced Colorectal Carcinoma, Recurrent Colorectal Carcinoma, Stage III Colorectal Cancer
Interventions
Aminolevulinic Acid, Biospecimen Collection, Computed Tomography, Fluorescence-Guided Surgery, Magnetic Resonance Imaging, Photodynamic Therapy, Surgical Procedure
Drug · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 7:15 AM EDT
Not yet recruiting Not applicable Interventional

Impact of a Human Origin Heat Inactivated Probiotic-Lactobacillus Paracasei D3.5 (LpD3.5) as Dietary Supplement on Gut Mucin and Intestinal Permeability in Adults With IBD

NCT07017959
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
LpD3.5 supplementation., Placebo
Dietary Supplement
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 1Phase 2 Interventional

LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors

NCT04666688
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumor, Pancreatic Cancer, Urothelial Carcinoma, Head and Neck Cancer, Colorectal Cancer
Interventions
LYT-200, Tislelizumab, Gemcitabine/nab-paclitaxel
Drug
Lead sponsor
PureTech
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
12
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 20, 2026, 7:15 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Cognition, Flavonoids, Exercise, Gut Microbiome

NCT06495190
View directory record Official record
Conditions
Cognitive Decline, Mild
Interventions
Blueberry, Walking, Placebo, Stretching
Dietary Supplement · Behavioral
Lead sponsor
Appalachian State University
Other
Eligibility
65 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Kannapolis, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Oct 20, 2026, 7:15 AM EDT
Terminated Phase 1 Interventional

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

NCT06270082
View directory record Official record
Conditions
Solid Tumor, Adult, Colorectal Cancer, Pancreatic Cancer, Malignant Melanoma, Ras (Kras or Nras) Gene Mutation, BRAF Gene Mutation, CRAF Gene Mutation, Non-Small Cell Lung Carcinoma, Thyroid Carcinoma, Gliomas, Malignant
Interventions
IK-595
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
15
States / cities
Duarte, California • Orange, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 1 Interventional

Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer

NCT00047762
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Erlotinib (aka Tarceva or OSI-774), Bevacizumab (aka Avastin or Rhu MAb VEGF)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
3
States / cities
Indianapolis, Indiana • Baltimore, Maryland • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 7:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Immune Regulation in Ulcerative Colitis or Crohn s Disease

NCT00001184
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis, Chrohn's Disease
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 75 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Not applicable Interventional

A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients

NCT00002084
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
46
States / cities
Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Gut Butyrate and Blood Pressure in African Americans

NCT04415333
View directory record Official record
Conditions
Hypertension
Interventions
Sodium Butyrate 5 mmol, Sodium Butyrate 80 mmol
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
30 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 20, 2026, 7:15 AM EDT
Not listed No phase listed Observational

Therapeutic Endoscopic Ultrasound for Gastrointestinal Disorders: A Multicenter Registry Study

NCT05051358
View directory record Official record
Conditions
Therapeutic Endoscopic Ultrasound, Advanced Endoscopy, Therapeutic Endoscopy, Interventional Endoscopy, Interventional Endoscopic Ultrasound, Gastro-Intestinal Disorder, Gastrointestinal Disease, Gastrointestinal Cancer, Gastrointestinal Dysfunction, Gastrointestinal Fistula, Gastrointestinal Infection, Gastrointestinal Injury, Pancreatic Disease, Bile Duct Diseases
Interventions
Therapeutic Endoscopic Ultrasound
Procedure
Lead sponsor
Advanced Endoscopy Research, Robert Wood Johnson Medical School Rutgers University
Other
Eligibility
Not listed
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 26, 2023 · Synced Oct 20, 2026, 7:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessing Infectious Risk and Visceral Closure in Natural Orifice Translumenal Endoscopic Surgery (NOTES)

NCT01102725
View directory record Official record
Conditions
Colonic Diseases, Rectal Diseases
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 16, 2014 · Synced Oct 20, 2026, 7:15 AM EDT
Completed No phase listed Observational

Genetic Markers in Patients With Colorectal Cancer

NCT00014079
View directory record Official record
Conditions
Colorectal Cancer
Interventions
DNA stability analysis, loss of heterozygosity analysis, microsatellite instability analysis
Genetic
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Not listed
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2005
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 20, 2026, 7:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of Aronia Berry Consumption on Inflammation, Metabolites, and the Gut Microbiome

NCT05255718
View directory record Official record
Conditions
Inflammation, Metabolic Disorder, Hypertriglyceridemia
Interventions
Aronia juice, Placebo
Dietary Supplement · Other
Lead sponsor
Montana State University
Other
Eligibility
18 Years to 60 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Oct 20, 2026, 7:15 AM EDT